Genprex, Inc. GNPX
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 |
| R&D | $9.4M | $10.5M | $17.6M | $11.5M | $9.0M | $7.3M | $2.0M | $971.4K | $289.9K | $354.9K |
| SG&A | $6.1M | $10.6M | $13.4M | $12.3M | $11.7M | $10.6M | $8.7M | $11.4M | $3.0M | $3.8M |
| Total operating expenses | $15.5M | $21.2M | $31.1M | $23.8M | $20.7M | $18.0M | $10.7M | $12.4M | $3.3M | $4.1M |
| Operating income | -$15.5M | -$21.2M | -$31.1M | -$23.8M | -$20.7M | -$18.0M | -$10.7M | -$12.4M | -$3.3M | -$4.1M |
| Interest expense | — | — | — | — | — | — | — | $38.0K | $1.9K | $0 |
| Pre-tax income | -$16.2M | -$21.4M | -$30.9M | -$23.7M | — | — | — | — | — | — |
| Income tax | $0 | $2.6K | $0 | $0 | — | — | — | — | — | — |
| Net income | -$16.2M | -$21.4M | -$30.9M | -$23.7M | -$20.7M | -$17.9M | -$10.7M | -$12.4M | -$3.3M | -$4.1M |
| EPS, basic | -17.40 | -266.89 | -22.56 | -19.80 | -0.44 | — | — | — | — | — |
| EPS, diluted | — | — | — | — | -0.42 | -0.51 | -0.66 | -0.90 | -0.29 | -0.38 |
| Shares, diluted (wtd. avg.) | 932,730 | 80,139 | 1.4M | 1.2M | 47.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.8M | $1.6M | $6.7M | $21.0M | — | — | — | — | $161.3K | $1.6M |
| Receivables | — | — | $0 | $34.9K | $0 | $127 | $655 | $9.3K | $8.8K | $8.2K |
| Total current assets | $8.4M | $2.1M | $7.5M | $21.5M | $39.1M | $27.7M | $3.0M | $8.8M | $193.6K | $1.6M |
| Property, plant and equipment | $0 | $0 | $7.9K | $23.0K | $48.6K | $39.4K | $44.7K | $24.4K | $7.8K | $5.2K |
| Other intangibles | — | $0 | $773.5K | $702.1K | $642.4K | $601.6K | $491.2K | $379.5K | $298.6K | $241.0K |
| Total assets | $10.2M | $4.1M | $10.7M | $25.1M | $42.9M | $31.4M | $3.5M | $9.3M | $1.3M | $1.9M |
| Accounts payable | $743.1K | $1.1M | $1.4M | $442.9K | $973.2K | $193.0K | $436.3K | $295.1K | $629.1K | $285.7K |
| Total current liabilities | $2.2M | $2.5M | $3.3M | $2.8M | $1.6M | $450.7K | $510.7K | $387.8K | $831.0K | $285.7K |
| Total liabilities | $2.2M | $2.5M | — | $2.2M | $1.6M | — | — | — | — | — |
| Retained earnings | -$171.0M | -$154.8M | -$133.7M | -$102.8M | -$79.1M | -$58.4M | -$40.5M | -$29.8M | -$17.5M | -$14.1M |
| Total equity | $8.0M | $1.6M | $7.4M | $22.3M | $41.3M | $30.9M | $3.0M | $8.9M | $428.6K | $1.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.3M | -$17.9M | -$24.7M | -$17.6M | -$14.3M | -$13.9M | -$6.9M | -$6.8M | -$2.2M | -$1.2M |
| Depreciation and amortisation | $0 | $6.7K | $15.0K | $25.6K | $22.5K | $22.8K | $13.1K | $5.9K | $3.2K | $862 |
| Stock-based compensation | — | $3.3M | $5.4M | $4.7M | $5.3M | $4.2M | $3.5M | $5.4M | $1.3M | $2.7M |
| Capital expenditure | — | — | — | $0 | $31.7K | $17.6K | $33.4K | $22.4K | $5.9K | $5.0K |
| Investing cash flow | $0 | $774.6K | -$71.2K | -$59.7K | -$83.8K | -$2.3M | -$946.9K | -$103.3K | -$63.4K | -$89.5K |
| Financing cash flow | $21.5M | $12.0M | $10.6M | $6.4K | $25.7M | $41.6M | $1.3M | $15.4M | $794.0K | $2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-013906.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | — | $0 | $0 | $0 | $0 | $0 | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$4.1M | -$3.3M | -$12.4M | -$10.7M | -$17.9M | -$20.7M | -$23.7M | -$30.9M | -$21.4M | -$16.2M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
- Delisting notice Item 3.01
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |